LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Article ; Online: Infrequent but serious? Beriberi And Thiamine deficiency among adolescents and young adults after bariatric surgery.

Ibrahim, Tawheeda / El Ansari, Walid / Abusabeib, Alyaa / Yousaf, Zohaib / Elhag, Wahiba

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

2023 Volume 20, Issue 2, Page(s) 115–126

Abstract: Background: Thiamine deficiency (TD) among adolescents following metabolic and bariatric surgery (MBS) has not been assessed.: Objective: We assessed TD among adolescents following MBS.: Setting: University Hospital.: Methods: A retrospective ... ...

Abstract	Background: Thiamine deficiency (TD) among adolescents following metabolic and bariatric surgery (MBS) has not been assessed. Objective: We assessed TD among adolescents following MBS. Setting: University Hospital. Methods: A retrospective chart review was conducted for all adolescents and young adults (aged 10-25 years) who had MBS and subsequently presented with TD at our institution (n = 30). Diagnosis used clinical, laboratory, brain imaging, and neurophysiology criteria. Of 1575 patients, 7 subsequently had TD. Another 23 adolescents had MBS at private hospitals or overseas and presented at our institution with TD. Results: Based on MBS undertaken at our institution, TD prevalence was .45 cases per 100 MBS. The mean age of patients was 19.5 ± 3.23 years, 53.3% were male, 96.7% had sleeve gastrectomy, and time from MBS to admission averaged 4.97 ± 11.94 months. Mean weight loss from surgery to admission was 33.68 ± 10.90 kg. Associated factors included poor oral intake (90%), nausea and vomiting (80%), and noncompliance with multivitamins (71%). Signs and symptoms included generalized weakness, nystagmus, numbness, and paraparesis (83.3%-80%). Seven patients had Wernicke encephalopathy full triad; 16 displayed a mixed picture of Wernicke encephalopathy and dry beriberi; and there were no cases of wet beriberi. Half the patients achieved complete resolution of symptoms, whereas 47% and 40% had residual weakness or persistent sensory symptoms, respectively. There was no mortality. Most common concurrent nutritional deficiencies were of vitamins K, D, and A. Conclusions: This is the first in-depth study of TD among adolescents after MBS. Although TD is uncommon among adolescents after MBS, it is serious, requiring diligent suspicion and prompt treatment. Bariatric teams should emphasize compliance with multivitamin regimens and follow it up.
MeSH term(s)	Humans ; Male ; Young Adult ; Adolescent ; Adult ; Female ; Beriberi/etiology ; Beriberi/diagnosis ; Beriberi/drug therapy ; Wernicke Encephalopathy/diagnosis ; Wernicke Encephalopathy/epidemiology ; Wernicke Encephalopathy/etiology ; Retrospective Studies ; Thiamine Deficiency/epidemiology ; Thiamine Deficiency/etiology ; Vitamins/therapeutic use ; Bariatric Surgery/adverse effects ; Thiamine/therapeutic use
Chemical Substances	Vitamins ; Thiamine (X66NSO3N35)
Language	English
Publishing date	2023-07-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	2274243-8
ISSN	1878-7533 ; 1550-7289
ISSN (online)	1878-7533
ISSN	1550-7289
DOI	10.1016/j.soard.2023.06.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6572: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Epidemiology, microbiological, clinical characteristics, and outcome of

Ibrahim, Tawheeda / Abdallah, Tasneem A / Abdallah, Ahmed / Qazi, Rabia / Alimam, Abeir / Mohammad, Hashim / Eltayeb, Faiha / Daghfal, Joanne / Ali, Maisa / Hadi, Hamad Abdel

IJID regions

2024 Volume 11, Page(s) 100355

Abstract: Objectives: Burkholderia: Methods: A retrospective study was conducted on adult patients across all hospitals at Hamad Medical Corporation between January 2012 and December 2018 to evaluate clinically relevant Bcc in non-CF adult patients.: Results! ...

Abstract	Objectives: Burkholderia Methods: A retrospective study was conducted on adult patients across all hospitals at Hamad Medical Corporation between January 2012 and December 2018 to evaluate clinically relevant Bcc in non-CF adult patients. Results: Over 7 years, 72 episodes of Conclusions: B. cepacia
Language	English
Publishing date	2024-03-26
Publishing country	England
Document type	Journal Article
ISSN	2772-7076
ISSN (online)	2772-7076
DOI	10.1016/j.ijregi.2024.03.010
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections.

Abdallah, Tasneem A K / Elajez, Reem / Ibrahim, Tawheeda B / Alimam, Abeir B / Omrani, Ali S

Journal of infection and public health

2021 Volume 14, Issue 11, Page(s) 1620–1622

Abstract: We reviewed the efficacy and safety of intravenous (IV) fosfomycin for the treatment of infections caused by Gram-negative bacteria (GNB) with difficult-to-treat resistance (DTR). Data were retrospectively retrieved for all hospitalized patients who ... ...

Abstract	We reviewed the efficacy and safety of intravenous (IV) fosfomycin for the treatment of infections caused by Gram-negative bacteria (GNB) with difficult-to-treat resistance (DTR). Data were retrospectively retrieved for all hospitalized patients who received IV fosfomycin for ≥48 h for the treatment of a DTR GNB between September 27, 2017 and January 31, 2020. A total of 30 patients were included, of which 63.3% were males, and the median age was 63.5 years (IQR 46-73). The median Charlson Comorbidity Score was 6 (IQR 3.8-9). The urinary tract (56.7%) was the most frequent site of infection, and the most frequent target organisms were Klebsiella pneumoniae (56.7%), and Escherichia coli (23.3%). The majority (76.%) received IV fosfomycin in combination with other antibacterial agents. Clinical improvement was observed in 22 (73.3%), eradication of baseline pathogens in 20 (66.7%), 30-day all-cause mortality in 7 (23.3%), and documented emergent resistance to fosfomycin in 5 (16.7%) patients. Treatment-related adverse events were infrequent and generally mild or moderate in severity. In conclusion, IV fosfomycin is a potentially efficacious and safe treatment option for the treatment of DTR GNB infections. Randomized trials are urgently required to confirm the utility of IV fosfomycin as monotherapy and in combination with other agents.
MeSH term(s)	Anti-Bacterial Agents/adverse effects ; Fosfomycin/adverse effects ; Gram-Negative Bacterial Infections/drug therapy ; Humans ; Klebsiella pneumoniae ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Retrospective Studies ; Urinary Tract Infections/drug therapy
Chemical Substances	Anti-Bacterial Agents ; Fosfomycin (2N81MY12TE)
Language	English
Publishing date	2021-10-02
Publishing country	England
Document type	Journal Article
ZDB-ID	2467587-8
ISSN	1876-035X ; 1876-0341
ISSN (online)	1876-035X
ISSN	1876-0341
DOI	10.1016/j.jiph.2021.09.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Tocilizumab for the treatment of severe coronavirus disease 2019.

Alattar, Rand / Ibrahim, Tawheeda B H / Shaar, Shahd H / Abdalla, Shiema / Shukri, Kinda / Daghfal, Joanne N / Khatib, Mohamed Y / Aboukamar, Mohamed / Abukhattab, Mohamed / Alsoub, Hussam A / Almaslamani, Muna A / Omrani, Ali S

Journal of medical virology

2020 Volume 92, Issue 10, Page(s) 2042–2049

Abstract: Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed ... ...

Abstract	Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0°C, 37.3°C (P = .043), and 37.0°C (P = .064), respectively. Corresponding median C-reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials.
MeSH term(s)	Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/therapeutic use ; C-Reactive Protein/analysis ; COVID-19/drug therapy ; Female ; Humans ; Male ; Middle Aged ; Qatar ; Respiration, Artificial ; Retrospective Studies
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antiviral Agents ; C-Reactive Protein (9007-41-4) ; tocilizumab (I031V2H011)
Keywords	covid19
Language	English
Publishing date	2020-05-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.25964
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Favipiravir for the treatment of coronavirus disease 2019 pneumonia; a propensity score-matched cohort study.

Alattar, Rand A / Abdalla, Shiema / Abdallah, Tasneem / Kazman, Rashid / Qadmour, Aseelah / Ibrahim, Tawheeda / Alhariri, Bassem / Shaar, Shahd H / Bajwa, Abeer / Alimam, Abeir / Qazi, Rabia / Ben Abid, Fatma / Daghfal, Joanne / Eldeeb, Ali / Shukri, Kinda / Elsayed, Ahmed / Rustom, Fatima / Alsamawi, Musaed / Abdelmajid, Alaaeldin /

Basulto, Miguel A P / Cobian, Armando A R / Abukhattab, Mohamed / Alkhal, Abdullatif / Almaslamani, Muna A / Omrani, Ali S

Journal of infection and public health

2022 Volume 15, Issue 10, Page(s) 1061–1064

Abstract: We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not ... ...

Abstract	We retrospectively investigated the clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Patients who between 23 May 2020 and 18 July 2020 received ≥ 24 h of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. The unmatched cohort included 1493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P < 0.001). Adverse events were common in both groups, but the 93.9% were Grades 1-3. Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
MeSH term(s)	Humans ; COVID-19 ; SARS-CoV-2 ; Propensity Score ; Cohort Studies ; Retrospective Studies ; Antiviral Agents/adverse effects ; Treatment Outcome
Chemical Substances	favipiravir (EW5GL2X7E0) ; Antiviral Agents
Language	English
Publishing date	2022-08-27
Publishing country	England
Document type	Journal Article
ZDB-ID	2467587-8
ISSN	1876-035X ; 1876-0341
ISSN (online)	1876-035X
ISSN	1876-0341
DOI	10.1016/j.jiph.2022.08.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Tocilizumab for the treatment of severe coronavirus disease 2019

J. med. virol

Abstract	Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1, 3, and 7 was 38.0°C, 37.3°C (P = .043), and 37.0°C (P = .064), respectively. Corresponding median C-reactive protein was 193 and 7.9 mg/L (P < .0001) and <6 mg/L (P = .0001). Radiological improvement was noted in 44% of patients by day 7% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P = .031) and 28% on day 14 (P = .001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #175880
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study

ALATTAR, Rand A / ABDALLA, Shiema / ABDALLAH, Tasneem AK / KAZMAN, Rashid / QADMOUR, Aseelah / IBRAHIM, Tawheeda BH / ALHARIRI, Bassem / SHAAR, Shahd / BAJWA, Abeer / ALIMAM, Abeir BH / QAZI, Rabia / BEN ABID, Fatma / DAGHFAL, Joanne / ELDEEB, Ali M / SHUKRI, Kinda / ELSAYED, Ahmed / RUSTOM, Fatima / ALSAMAWI, Musaed / ABDELMAJID, Alaaeldin /

BASULTO, Miguel AP / COBIAN, Armando AR / ABUKHATTAB, Mohamed / ALMASLAMANI, Muna A / ALKHAL, Abdullatif / OMRANI, Ali S

medRxiv

Abstract: Background We investigated clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received 24 hours or more of favipiravir were assigned to the favipiravir group, while those who ... ...

Abstract	Background We investigated clinical outcomes of favipiravir in patients with COVID-19 pneumonia. Methods Patients who between 23 May 2020 and 18 July 2020 received 24 hours or more of favipiravir were assigned to the favipiravir group, while those who did not formed the non-favipiravir group. The primary outcome was 28-day clinical improvement, defined as two-category improvement from baseline on an 8-point ordinal scale. Propensity scores (PS) for favipiravir therapy were used for 1:1 matching. Cox regression was used to examine associations with the primary endpoint. Results The unmatched cohort included 1,493 patients, of which 51.7% were in the favipiravir group, and 48.3% were not receiving supplemental oxygen at baseline. Favipiravir was started within a median of 5 days from symptoms onset. Significant baseline differences between the two unmatched groups existed, but not between the PS-matched groups (N = 774). After PS-matching, there were no significant differences between the two groups in the proportion with 28-day clinical improvement (93.3% versus 92.8%, P 0.780), or 28-day all-cause mortality (2.1% versus 3.1%, P 0.360). Favipiravir was associated with more viral clearance by day 28 (79.8% versus 64.1%, P <0.001). In the adjusted Cox proportional hazards model, favipiravir therapy was not associated 28-day clinical improvement (adjusted hazard ratio 0.978, 95% confidence interval 0.862 to 1.109, P 0.726). Adverse events were common in both groups, but the 93.9% were Grades 1 to 3. Conclusion Favipiravir therapy for COVID-19 pneumonia is well tolerated but is not associated with an increased likelihood of clinical improvement or reduced all-cause mortality by 28 days.
Keywords	covid19
Language	English
Publishing date	2021-11-30
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2021.11.29.21267042
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study.

Omrani, Ali S / Almaslamani, Muna A / Daghfal, Joanne / Alattar, Rand A / Elgara, Mohamed / Shaar, Shahd H / Ibrahim, Tawheeda B H / Zaqout, Ahmed / Bakdach, Dana / Akkari, Abdelrauof M / Baiou, Anas / Alhariri, Bassem / Elajez, Reem / Husain, Ahmed A M / Badawi, Mohamed N / Abid, Fatma Ben / Abu Jarir, Sulieman H / Abdalla, Shiema / Kaleeckal, Anvar /

Choda, Kris / Chinta, Venkateswara R / Sherbash, Mohamed A / Al-Ismail, Khalil / Abukhattab, Mohammed / Ait Hssain, Ali / Coyle, Peter V / Bertollini, Roberto / Frenneaux, Michael P / Alkhal, Abdullatif / Al-Kuwari, Hanan M

BMC infectious diseases

2020 Volume 20, Issue 1, Page(s) 777

Abstract: Background: There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim of this study was to describe national, 60-day all-cause mortality associated with COVID-19, and to ... ...

Abstract	Background: There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim of this study was to describe national, 60-day all-cause mortality associated with COVID-19, and to identify risk factors associated with admission to an intensive care unit (ICU). Methods: This was a retrospective cohort study including the first consecutive 5000 patients with COVID-19 in Qatar who completed 60 days of follow up by June 17, 2020. The primary outcome was all-cause mortality at 60 days after COVID-19 diagnosis. In addition, we explored risk factors for admission to ICU. Results: Included patients were diagnosed with COVID-19 between February 28 and April 17, 2020. The majority (4436, 88.7%) were males and the median age was 35 years [interquartile range (IQR) 28-43]. By 60 days after COVID-19 diagnosis, 14 patients (0.28%) had died, 10 (0.2%) were still in hospital, and two (0.04%) were still in ICU. Fatal COVID-19 cases had a median age of 59.5 years (IQR 55.8-68), and were mostly males (13, 92.9%). All included pregnant women (26, 0.5%), children (131, 2.6%), and healthcare workers (135, 2.7%) were alive and not hospitalized at the end of follow up. A total of 1424 patients (28.5%) required hospitalization, out of which 108 (7.6%) were admitted to ICU. Most frequent co-morbidities in hospitalized adults were diabetes (23.2%), and hypertension (20.7%). Multivariable logistic regression showed that older age [adjusted odds ratio (aOR) 1.041, 95% confidence interval (CI) 1.022-1.061 per year increase; P < 0.001], male sex (aOR 4.375, 95% CI 1.964-9.744; P < 0.001), diabetes (aOR 1.698, 95% CI 1.050-2.746; P 0.031), chronic kidney disease (aOR 3.590, 95% CI 1.596-8.079, P 0.002), and higher BMI (aOR 1.067, 95% CI 1.027-1.108 per unit increase; P 0.001), were all independently associated with increased risk of ICU admission. Conclusions: In a relatively younger national cohort with a low co-morbidity burden, COVID-19 was associated with low all-cause mortality. Independent risk factors for ICU admission included older age, male sex, higher BMI, and co-existing diabetes or chronic kidney disease.
MeSH term(s)	Adolescent ; Adult ; Aged ; Betacoronavirus ; COVID-19 ; Child ; Cohort Studies ; Coronavirus Infections/diagnosis ; Coronavirus Infections/epidemiology ; Female ; Hospitalization ; Humans ; Intensive Care Units ; Logistic Models ; Male ; Middle Aged ; Odds Ratio ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/epidemiology ; Pregnancy ; Pregnancy Complications, Infectious ; Qatar/epidemiology ; Retrospective Studies ; Risk Factors ; SARS-CoV-2 ; Young Adult
Keywords	covid19
Language	English
Publishing date	2020-10-19
Publishing country	England
Document type	Journal Article
ZDB-ID	2041550-3
ISSN	1471-2334 ; 1471-2334
ISSN (online)	1471-2334
ISSN	1471-2334
DOI	10.1186/s12879-020-05511-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The First Consecutive 5000 Patients with Coronavirus Disease 2019 from Qatar; a Nation-wide Cohort Study

Omrani, Ali S. / Almaslamani, Muna A. / Daghfal, Joanne / Alattar, Rand A. / Elgara, Mohamed / Shaar, Shahd H. / Ibrahim, Tawheeda / Zaqout, Ahmed / Bakdach, Dana / Akkari, Abdelrauof / Baiou, Anas / Alhariri, Bassem / Elajez, Reem / Husain, Ahmed / Badawi, Mohamed N. / Ben Abid, Fatma / Abu Jarir, Sulieman / Abdalla, Shiema / Kaleeckal, Anvar /

Choda, Kris / Chinta, Venkateswara R. / Sherbash, Mohamed A. / Al Ismail, Khalil / Abukhattab, Mohammed / Ait Hssain, Ali / Coyle, Peter V. / Bertollini, Roberto / Frenneaux, Michael P. / Alkhal, Abdullatif / Al Kuwari, Hanan M.

medRxiv

Abstract: Background There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim of this study was to describe national, 60-day all-cause mortality associated with COVID-19, and to ... ...

Abstract	Background There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim of this study was to describe national, 60-day all-cause mortality associated with COVID-19, and to identify risk factors associated with admission to an intensive care unit (ICU). Methods This was a retrospective cohort study including the first consecutive 5000 patients with COVID-19 in Qatar who completed 60 days of follow up by June 17, 2020. Outcomes included all-cause mortality at 60 days after COVID-19 diagnosis, and risk factors for admission to ICU. Results Included patients were diagnosed with COVID-19 between February 28 and April 17, 2020. The majority (4436, 88.7%) were males and the median age was 35 years [interquartile range (IQR) 28-43]. By 60 days after COVID-19 diagnosis, 14 patients (0.28%) had died, 10 (0.2%) were still in hospital, and two (0.04%) were still in ICU. Fatal COVID-19 cases had a median age of 59.5 years (IQR 55.8-68), and were mostly males (13, 92.9%). All included pregnant women (26, 0.5%), children (131, 2.6%), and healthcare workers (135, 2.7%) were alive and not hospitalized at the end of follow up. A total of 1424 patients (28.5%) required hospitalization, out of which 108 (7.6%) were admitted to ICU. Most frequent co-morbidities in hospitalized adults were diabetes (23.2%), and hypertension (20.7%). Multivariable logistic regression showed that older age [adjusted odds ratio (aOR) 1.041, 95% confidence interval (CI) 1.022-1.061 per year increase; P <0.001], male sex (aOR 4.375, 95% CI 1.964-9.744; P <0.001), diabetes (aOR 1.698, 95% CI 1.050-2.746; P 0.031), chronic kidney disease (aOR 3.590, 95% CI 1.596-8.079, P 0.002), and higher BMI (aOR 1.067, 95% CI 1.027-1.108 per unit increase; P 0.001), were all independently associated with increased risk of ICU admission. Conclusions In a relatively younger national cohort with a low co-morbidity burden, COVID-19 was associated with low all-cause mortality. Independent risk factors for ICU admission included older age, male sex, higher BMI, and co-existing diabetes or chronic kidney disease.
Keywords	covid19
Language	English
Publishing date	2020-07-16
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2020.07.15.20154690
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study

BMC Infect Dis

Abstract: BACKGROUND: There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim of this study was to describe national, 60-day all-cause mortality associated with COVID-19, and to ... ...

Abstract	BACKGROUND: There are limited data on Coronavirus Disease 2019 (COVID-19) outcomes at a national level, and none after 60 days of follow up. The aim of this study was to describe national, 60-day all-cause mortality associated with COVID-19, and to identify risk factors associated with admission to an intensive care unit (ICU). METHODS: This was a retrospective cohort study including the first consecutive 5000 patients with COVID-19 in Qatar who completed 60 days of follow up by June 17, 2020. The primary outcome was all-cause mortality at 60 days after COVID-19 diagnosis. In addition, we explored risk factors for admission to ICU. RESULTS: Included patients were diagnosed with COVID-19 between February 28 and April 17, 2020. The majority (4436, 88.7%) were males and the median age was 35 years [interquartile range (IQR) 28-43]. By 60 days after COVID-19 diagnosis, 14 patients (0.28%) had died, 10 (0.2%) were still in hospital, and two (0.04%) were still in ICU. Fatal COVID-19 cases had a median age of 59.5 years (IQR 55.8-68), and were mostly males (13, 92.9%). All included pregnant women (26, 0.5%), children (131, 2.6%), and healthcare workers (135, 2.7%) were alive and not hospitalized at the end of follow up. A total of 1424 patients (28.5%) required hospitalization, out of which 108 (7.6%) were admitted to ICU. Most frequent co-morbidities in hospitalized adults were diabetes (23.2%), and hypertension (20.7%). Multivariable logistic regression showed that older age [adjusted odds ratio (aOR) 1.041, 95% confidence interval (CI) 1.022-1.061 per year increase; P < 0.001], male sex (aOR 4.375, 95% CI 1.964-9.744; P < 0.001), diabetes (aOR 1.698, 95% CI 1.050-2.746; P 0.031), chronic kidney disease (aOR 3.590, 95% CI 1.596-8.079, P 0.002), and higher BMI (aOR 1.067, 95% CI 1.027-1.108 per unit increase; P 0.001), were all independently associated with increased risk of ICU admission. CONCLUSIONS: In a relatively younger national cohort with a low co-morbidity burden, COVID-19 was associated with low all-cause mortality. Independent risk factors for ICU admission included older age, male sex, higher BMI, and co-existing diabetes or chronic kidney disease.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #873955
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

To top

Your last searches

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

Kategorien

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED